AN ESTIMATE OF AVOIDED COSTS FOR DRUGS IN PATIENTS INCLUDED IN NON-SMALL LUNG CANCER CLINICAL TRIALS

A.M. Álamo, E. Mateos, B. Nucete, M.E. Luján, M. Lombardero, C. Otero
Servicio de Farmacia. Servicio de Oncología. Complejo Hospitalario Universitario Insular Materno Infantil de Gran Canaria

BACKGROUND

✓ The economic impact of non-small cell lung cancer (NSCLC) is increasing. Clinical trials (CT) are essential for evaluating the efficacy and safety of new treatments, but they can also have an economic benefit by avoiding drug costs.

PURPOSE

✓ Our aim was to determine the avoided cost attributable to drugs assigned to patients with NSCLC enrolled in CT during the 2016.

MATERIAL AND METHODS

✓ Descriptive, observational, retrospective study of CT done on patients with NSCLC during 2016
✓ Statistical analysis was performed using the program SPSS® Statistics24

Data Collected

✓ CT Identification
✓ Sponsor: Pharmaceutical Industry, Cooperative Group
✓ Phase
✓ Study design
✓ Number of patient

Cost analysis:
✓ Nº of dispensations
✓ Nº of cycles
✓ Drug/s as well as the amount dispensed
✓ Chemotherapy Regimen
✓ Treatment duration
✓ Average drug Prices

✓ Inclusion Criteria: CT with at least one patient included, and those to whom the antineoplastic treatment was provided by the promoter

Limitation: We did not take the cost of working in aseptic conditions or the cost of administering the drugs into account..

RESULTS

14 CT NSCLC

No inclusion
2 CT

Inclusion
12 CT

✓ 11 phase III y 1 phase II
✓ Sponsor: 11 Pharmaceutical Industry y 1 Cooperative Groups
✓ 69 patients
✓ 369 cycles administered
✓ 5,35 ± 5,71 cycles/patients

Overall Avoided Cost

€ 474 428.65
Average Cost per Clinical Trial
€ 39 535.72
Average Cost per Patient
€ 7 875.77

CONCLUSION

✓ The avoided cost in research drugs has a great impact on pharmaceutical expenses. CT provide an exceptional context for advancing clinical research, as well as considerable savings for hospitals and healthcare system.

REFERENCES AND /OR ACKNOWLEDGEMENTS